Literature DB >> 22529080

A financial analysis of revision hip arthroplasty: the economic burden in relation to the national tariff.

I S Vanhegan1, A K Malik, P Jayakumar, S Ul Islam, F S Haddad.   

Abstract

Revision arthroplasty of the hip is expensive owing to the increased cost of pre-operative investigations, surgical implants and instrumentation, protracted hospital stay and drugs. We compared the costs of performing this surgery for aseptic loosening, dislocation, deep infection and peri-prosthetic fracture. Clinical, demographic and economic data were obtained for 305 consecutive revision total hip replacements in 286 patients performed at a tertiary referral centre between 1999 and 2008. The mean total costs for revision surgery in aseptic cases (n = 194) were £11 897 (sd 4629), for septic revision (n = 76) £21 937 (sd 10 965), for peri-prosthetic fracture (n = 24) £18 185 (sd 9124), and for dislocation (n = 11) £10 893 (sd 5476). Surgery for deep infection and peri-prosthetic fracture was associated with longer operating times, increased blood loss and an increase in complications compared to revisions for aseptic loosening. Total inpatient stay was also significantly longer on average (p < 0.001). Financial costs vary significantly by indication, which is not reflected in current National Health Service tariffs.

Entities:  

Mesh:

Year:  2012        PMID: 22529080     DOI: 10.1302/0301-620X.94B5.27073

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  87 in total

Review 1.  [Septic endoprosthesis exchange : Preoperative diagnosis and reimplantation].

Authors:  H M L Mühlhofer; J Schauwecker; I J Banke; R von Eisenhart-Rothe
Journal:  Orthopade       Date:  2015-12       Impact factor: 1.087

2.  Optimal culture incubation time in orthopedic device-associated infections: a retrospective analysis of prolonged 14-day incubation.

Authors:  Nora Schwotzer; Peter Wahl; Dominique Fracheboud; Emanuel Gautier; Christian Chuard
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

Review 3.  [Periprosthetic infections of the hip joint : Clinical approach].

Authors:  H M L Mühlhofer; H Gollwitzer; F Lenze; S Feihl; F Pohlig; R von Eisenhart-Rothe; J Schauwecker
Journal:  Orthopade       Date:  2015-05       Impact factor: 1.087

4.  Assessing the value of a total joint replacement.

Authors:  David B Bumpass; Ryan M Nunley
Journal:  Curr Rev Musculoskelet Med       Date:  2012-12

Review 5.  Contributions of human tissue analysis to understanding the mechanisms of loosening and osteolysis in total hip replacement.

Authors:  Jiri Gallo; Jana Vaculova; Stuart B Goodman; Yrjö T Konttinen; Jacob P Thyssen
Journal:  Acta Biomater       Date:  2014-02-10       Impact factor: 8.947

Review 6.  [Allogeneic bone transplantation in hip revision surgery : Indications and potential for reconstruction].

Authors:  G A Ahmed; B Ishaque; M Rickert; C Fölsch
Journal:  Orthopade       Date:  2018-01       Impact factor: 1.087

7.  The value of a standardized and reproducible surgical technique in treatment of Vancouver B2 periprosthetic fractures: our experience.

Authors:  Stefano Biggi; Andrea Camera; Riccardo Tedino; Andrea Capuzzo; Stefano Tornago
Journal:  Eur J Trauma Emerg Surg       Date:  2018-06-19       Impact factor: 3.693

8.  [Surgery of sepsis in orthopedics and trauma - A highlight : Current survey by the section for bone and soft tissue infections of the German Society for Orthopedics and Trauma].

Authors:  M Militz; W Popp; R Hoffmann; R Ascherl; A Tiemann
Journal:  Unfallchirurg       Date:  2017-03       Impact factor: 1.000

Review 9.  Surgical approach in primary total hip arthroplasty: anatomy, technique and clinical outcomes.

Authors:  Stephen Petis; James L Howard; Brent L Lanting; Edward M Vasarhelyi
Journal:  Can J Surg       Date:  2015-04       Impact factor: 2.089

Review 10.  [Epidemiology and prevention of prosthetic joint infection].

Authors:  I J Banke; R von Eisenhart-Rothe; H M L Mühlhofer
Journal:  Orthopade       Date:  2015-12       Impact factor: 1.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.